3Vote!
Medical News Today (Free subscription) | 11/20/2009
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated...
5Vote!
Seattle Post-Intelligencer (Free subscription) | 11/18/2009
NEW YORK -- Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.
7Vote!
Miami Herald (Free subscription) | 11/18/2009
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment.
5Vote!
Business Wire (Free subscription) | 11/17/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic)...
+Vote!
Daily Advance - Business (Free subscription) | 11/19/2009
NEW YORK — Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Admini...
5Vote!
San Fransisco Chronicle (Free subscription) | 11/18/2009
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. The drug is already approved as a treatment for rheumatoid arthritis and... BiogenIdec - Food and Drug Administration - Genentech - Rituximab - Health
7Vote!
Seattle Times (Free subscription) | 11/18/2009
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment.
4Vote!
Business Wire (Free subscription) | 11/18/2009
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC)...
3Vote!
Medical News Today (Free subscription) | 11/17/2009
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line...
5Vote!
PharmaGossip (Free subscription) | 10/28/2009
... use Avastin instead of Lucentis, an alternative treatment. Both drugs are manufactured by Genentech however, Lucentis cost $2,000 a dose roughly 20 times as much as Avastin. Kohl wrote to CMS earlier this month to express his concern over the coding change. “I’m pleased that CMS heeded the concerns of the medical eye care community and the Aging Committee. Even seniors who have...
5Vote!
The San Francisco Business Times (Free subscription) | 10/21/2009
NGM Biopharmaceuticals Inc. put former Genentech Inc. CEO Arthur Levinson on its board of directors.
4Vote!
Business Wire (Free subscription) | 10/17/2009
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc. a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq:BIIB) announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan® (rituximab) plus...
5Vote!
The Earth Times Online Newspaper (Free subscription) | 10/17/2009
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. - Genentech, Inc. a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq:BIIB) announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a sup
3Vote!
PRWeb - Daily News Feed (Free subscription) | 11/23/2009
The FDA is currently evaluating interim safety findings in an ongoing study of XOLAIR problems. XOLAIR (omalizumab) is an injected drug for asthma related allergies. The interim results of this study, which is being conducted by the drug’s manufacturer, Genentech, Inc., suggests an increased number of cardiovascular (heart attack) and cerebrovascular (stroke) adverse events in a group...
4Vote!
The Intangible Economy (Free subscription) | 11/09/2009
While intangible asset securitization has been quiet, is it not extinct. Last week, PDL BioPharma, Inc. announced that it closed on $300 million securitization of some of its patents. From what I can tell, it looks like exactly the type...
